Evidence map›Paper›PMID 33068714›Full record

ArticleJournal of clinical epidemiology2021

Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive.

Michael Ewers, John P A Ioannidis, Nikolaus Plesnila

Abstract read
In one paragraph

Article in Journal of clinical epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Institutionalizing Open Science in Africa: Limitations and Prospects.Frontiers in research metrics and analytics · 2022
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael EwersInstitute for Stroke and Dementia Research, University Hospital Munich, Ludwig Maximilian University, Munich, Germany; LMU Open Science Center (OSC), Ludwig Maximilian University, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich. Electronic address: michael.ewers@med.uni-muenchen.de.
John P A IoannidisDepartment of Medicine, Department of Epidemiology and Population Health, Department of Biomedical Data Science, Department of Statistics, Meta-Research Innovation Center at Stanford (METRICS), Stanford University, CA, USA. Electronic address: jioannid@stanford.edu.
Nikolaus PlesnilaInstitute for Stroke and Dementia Research, University Hospital Munich, Ludwig Maximilian University, Munich, Germany; LMU Open Science Center (OSC), Ludwig Maximilian University, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentClinical Trials as TopicCOVID-19HumansHydroxychloroquineInformation DisseminationMedical RecordsObservational Studies as TopicOpen Access PublishingSurvival AnalysisTime FactorsHydroxychloroquine

Identifiers

PMID33068714
PMCPMC7554475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.